Focused On-demand Library for Tubulin alpha-1B chain

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

PARTNER
Receptor.AI
 
UPACC
P68363

UPID:
TBA1B_HUMAN

ALTERNATIVE NAMES:
Alpha-tubulin ubiquitous; Tubulin K-alpha-1; Tubulin alpha-ubiquitous chain

ALTERNATIVE UPACC:
P68363; P04687; P05209; Q27I68; Q8WU19

BACKGROUND:
The Tubulin alpha-1B chain, identified by its alternative names such as Alpha-tubulin ubiquitous and Tubulin alpha-ubiquitous chain, is fundamental to the assembly of microtubules. These cylindrical structures, built from alpha- and beta-tubulin heterodimers, are crucial for various cellular processes, including mitosis and motility. The growth of microtubules is regulated by the addition of GTP-tubulin dimers, a process stabilized by alpha-tubulin's GTPase activity.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Tubulin alpha-1B chain holds promise for the development of novel therapeutic approaches. Given its essential role in microtubule assembly and cellular processes, targeting this protein could lead to breakthroughs in treating diseases characterized by abnormal cell growth and division, such as cancer.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 8273 of 8789